ALLOGENE THERAPEUTICS INC (ALLO) Stock News

USA - NASDAQ:ALLO - US0197701065 - Common Stock

1.26 USD

-0.03 (-2.33%)

Last: 10/21/2025, 8:00:00 PM

1.26 USD

0 (0%)

After Hours: 10/21/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ALLO Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Zacks Investment Research - Mentions: ADCT ZTS CMMB

Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain

8 days ago - By: Zacks Investment Research - Mentions: SNY TEVA CMMB

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder

11 days ago - By: Zacks Investment Research - Mentions: CDTX AKRO CMMB

CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza

11 days ago - By: Benzinga - Mentions: HSBC KEYS AKRO DOCS

This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

a month ago - By: Zacks Investment Research - Mentions: BMY PFE LLY ABBV ...

Investing in Oncology: 3 Cancer Stocks With Promising Pipelines

2 months ago - By: The Motley Fool

Allogene Narrows Loss in Fiscal Q2

2 months ago - By: Benzinga

A Look at Allogene Therapeutics's Upcoming Earnings Report

2 months ago - By: Zacks Investment Research - Mentions: ADPT AQST AKRO

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

2 months ago - By: Zacks Investment Research - Mentions: AGIO ADPT AKRO

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

2 months ago - By: Zacks Investment Research - Mentions: AMRN AKRO ALGS

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus

2 months ago - By: The Motley Fool

Allogene Q2 Cash Tops $300 Million

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

2 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

3 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

3 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

3 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

3 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

3 months ago - By: Yahoo Finance - Mentions: REGN BMY BIIB

Regeneron cancer bispecific rejected again; Allogene discloses trial death

5 months ago - By: Zacks Investment Research

All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy

5 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

5 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

5 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

5 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

5 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

5 months ago - By: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel